- Neogen Corporation recently expanded the availability of FIFRA Section 2(ee) recommendations for its Prozap Insectrin X Concentrate and Prozap Screw Worm and Ear Tick Aerosol in Texas and Florida, giving livestock and horse owners more options to support New World Screwworm and fly management efforts beyond standard EPA label uses.
- This move strengthens Neogen’s role in specialized animal safety and pest control programs, potentially reinforcing demand for its Prozap portfolio within broader herd health and fly management practices in two key livestock states.
- We’ll now explore how this expanded use of Prozap products for New World Screwworm response could influence Neogen’s broader investment narrative.
This technology could replace computers: discover 29 stocks that are working to make quantum computing a reality.
Neogen Investment Narrative Recap
To own Neogen, you need to believe it can turn its food and animal safety platforms into a durable, higher quality business while fixing integration and margin pressures. The expanded Prozap 2(ee) uses in Texas and Florida look incremental rather than transformational, but they do align with efforts to stabilize Animal Safety. The key near term catalyst remains operational improvement in the 3M Food Safety integration, while persistent cattle herd weakness and broader macro softness are still the biggest swing risks.
Among recent developments, Neogen’s raised fiscal 2026 revenue guidance to US$857 million to US$860 million stands out against its ongoing quarterly losses. This cautious improvement in outlook sits alongside the Prozap 2(ee) expansion, which points to management trying to support Animal Safety while Food Safety integration and automation work to relieve cost and margin pressure. How much these smaller product moves can offset headwinds in a still contracting Animal Safety segment is an open question.
But while Prozap’s broader use is encouraging, investors should still be aware of the risk that persistent Animal Safety weakness and cattle herd pressures could...
Read the full narrative on Neogen (it's free!)
Neogen's narrative projects $824.9 million revenue and $105.5 million earnings by 2029.
Uncover how Neogen's forecasts yield a $12.00 fair value, a 34% upside to its current price.
Exploring Other Perspectives
Some of the most optimistic analysts were assuming roughly flat revenue around US$865 million and a swing to US$106 million in earnings, yet the new Prozap 2(ee) news could either support that upbeat view or highlight how much still depends on resolving product quality and recall risks in Animal Safety.
Explore 2 other fair value estimates on Neogen - why the stock might be worth just $12.00!
Reach Your Own Conclusion
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Neogen research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Neogen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Neogen's overall financial health at a glance.
Want Some Alternatives?
Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:
- Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
- We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
- AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com